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Abstract
Background: This is the first documented case of a patient with hemophagocytic lymphohistiocytosis in association
with coeliac disease. There was complete clinical and biochemical remission of hemophagocytic lymphohistiocytosis
following the introduction of a gluten-free diet.
Case presentation: A 7-year-old white girl presented with fevers and maculopapular rash with a recent history of
tonsillitis. Blood tests revealed thrombocytopenia (64×109/L), anemia (80 g/L), hypofibrinogenemia (1 g/L), and
hyperferritinemia (71,378 μg/L). A bone marrow revealed evidence of hemophagocytosis, but the results of tests
for the genetic or familial-associated hemophagocytic lymphohistiocytosis syndromes were negative. The results
of screening tests for known secondary causes were negative. She was diagnosed as having hemophagocytic
lymphohistiocytosis and following treatment with the hemophagocytic lymphohistiocytosis-2004 protocol these
symptoms, in addition to the biochemical and hematological markers, completely resolved.
She presented again 10 months later with fever, rash, and biochemical abnormalities suggestive of hemophagocytic
lymphohistiocytosis. Her tissue transglutaminase was markedly raised and the results of blood tests revealed a genetic
susceptibly to coeliac disease in the form of HLA-DQ2 positivity. She commenced a gluten-free diet and there was
complete symptomatic and biochemical response without any further chemotherapy. She had further episodic rashes,
each associated with the accidental intake of gluten.
Conclusions: This is to the best of our knowledge the first documented case of hemophagocytic lymphohistiocytosis
in association with coeliac disease. No other secondary cause found; she initially responded to chemoimmunotherapy
specific for hemophagocytic lymphohistiocytosis but relapsed within a few months of cessation of treatment and then
achieved complete remission on gluten withdrawal alone.
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Background
Hemophagocytic lymphohistiocytosis (HLH) is a multisys-
tem inflammatory disorder caused by persistent activation
of the immune system, particularly macrophages and T
cells [1]. Hemophagocytosis by macrophages is the hall-
mark of this syndrome and is most commonly identified
in the bone marrow. Decreased natural killer (NK) cell ac-
tivity resulting in reduction of cellular cytotoxicity causing
persistent antigen presentation and cytokine release lead-
ing to macrophage activation is an important disease
mechanism [1, 2]. Macrophage activation leads to the
secretion of cytokines such as tumor necrosis factor
alpha and interleukins (ILs), particularly IL-1 and IL-6,
causing further T cell and macrophage activation [1].
The hyperactive immune system causes the classic
clinical features of persistent fever, rash, arthralgia
and splenomegaly. Laboratory investigations show cy-
topenia, hypofibrinogenemia, hypertriglyceridemia, and
hemophagocytosis [2]. Diagnostic criteria outlined by
the Histiocyte Society, based on clinical and laboratory
findings, are well described in the literature [2].
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Case presentation
We present the interesting case of a 7-year-old white girl
with HLH in association with coeliac disease (CD). She first
presented with a 2-week history of fever, associated with
tonsillitis, which was not responding to antibiotics. She also
had arthralgia and weight loss; an examination revealed a
widespread maculopapular rash with no other specific fea-
tures and no hepatosplenomegaly. She had previously been
well, with no significant family history or long-term
medications.
Blood tests revealed thrombocytopenia (64×109/L),
anemia (80 g/L), liver function derangement (alanine ami-
notransferase 1038 IU/ml), and hypofibrinogenemia (1 g/L).
She had a raised ferritin level (71,378 μg/L), and a bone
marrow biopsy showed occasional hemophagocytosis. Her
perforin expression was normal by flow cytometry, and
cytotoxic T lymphocyte (CTL) and NK cell granule release
on stimulation by mitogens was normal. Genotyping of the
PRF gene encoding perforin protein was wildtype. The re-
sult of an autoimmune screen, including rheumatoid factor,
anti-neutrophil cytoplasmic antibody, anti-double-stranded
DNA, and anti-citrullinated protein antibody was negative.
The results of a viral screen including Epstein–Barr virus
(EBV), parvovirus, human herpes virus 6, enterovirus,
adenovirus, cytomegalovirus (CMV), human immuno-
deficiency virus, and hepatitis screen were negative.
She commenced treatment on the HLH-2004 protocol,
with etoposide, dexamethasone, and ciclosporin given over
40 weeks for a diagnosis of HLH for which no underlying
cause was identified. She completed her treatment with
a good clinical and biochemical response. Ten months
later, she re-presented with a history of fevers, headaches,
and lethargy. Blood tests showed high ferritin (6702 μg/L)
and lactate dehydrogenase (1002 units/L) levels. She had
no cytopenia and a repeat bone marrow aspirate showed
no evidence of hemophagocytosis.
Her subsequent clinical course was complicated by re-
current fevers, arthralgia, widespread macular rash, and
weight loss. Her ferritin and lactate dehydrogenase levels
remained markedly raised and the results of repeat vir-
ology investigations were negative. A repeat autoimmune
screen revealed markedly raised tissue transglutaminase
(tTG) antibodies of 108 Units/ml (normal range 0 to 6.9
Units/ml). A jejunal biopsy was deemed too high risk
and a gluten-free diet was urgently commenced. Genetic
testing revealed a susceptibility to CD, in the form of
human leukocyte antigen (HLA)-DQ2 positivity, and she
was therefore diagnosed as having CD.
She continued a gluten-free diet following which her
clinical features improved and her biochemical markers,
including tTG antibodies, gradually returned to normal.
She had no further recurrences of her HLH symptoms
since the introduction of a gluten-free diet. However,
she continued to have intermittent episodes of macular
rash and arthralgia, particularly associated with acciden-
tal ingestion of gluten. Two years subsequent to this she
developed symptoms suggestive of juvenile idiopathic
arthritis (JIA) without HLH or macrophage activation
syndrome (MAS) and received treatment with systemic
steroids in addition to methotrexate, with clinical reso-
lution. Her autoimmune profile remained negative. Figure 1
elucidates her clinical course.
Discussion
HLH has many secondary causes which are well described
in the literature, including connective tissue diseases. The
morbidity of these syndromes can be significant and ac-
curate diagnosis is important. The recognition of CD-
associated HLH has yet to be made. This is the first
reported case of HLH secondary to CD, with dramatic
improvement of symptoms and biochemical features
following the introduction of a gluten-free diet.
An important differential diagnosis of HLH is MAS
seen with autoimmune diseases, such as rheumatic fever.
Although it can be argued that the hypercytokinemic
presentation in this case was as a result of MAS rather
than HLH, all the HLH criteria at the time of the original
presentation were met and symptoms only resolved on full
treatment with standard chemotherapy. In addition, she
relapsed a few months after cessation of treatment and
her symptoms resolved on gluten withdrawal alone.
However, primary HLH is genetic, commonly autosomal
recessive, and specific genes have been identified [1, 2]. In
familial HLH, mutations in genes encoding proteins respon-
sible for CTL and NK cell cytotoxicity are present [1, 2].
Treatment of primary HLH by chemotherapy alone invari-
ably leads to relapse and a definitive cure can only be
achieved by hemopoietic stem cell transplantation [2]. Sec-
ondary HLH occurs when no family history or genetic
markers are present and an underlying secondary cause is
found [2]. Common secondary causes include: infection
with tuberculosis, EBV, CMV, and adenovirus [1, 2]; lymph-
omas; JIA; and autoimmune diseases [1]. MAS has been re-
ported to be present in 10 % of patients with JIA [3].
Secondary HLH has a high mortality and morbidity in the
acute setting; however, following treatment of the acute ill-
ness there should be a low risk of recurrence. Similar clinical
features can be seen in severe sepsis and viral infections [2].
It is also possible to find hemophagocytosis on a bone mar-
row aspirate as a reactive feature in acutely unwell patients,
and patients with non-hematological disorders [1].
CD is a systemic autoimmune disorder triggered by
gluten and characterized by enteropathy and a host of
systemic features involving skin, bone, and joints and is
strongly associated with the presence of HLA-DQ2 or
DQ8 haplotypes [4]. HLH has been described as a present-
ing feature of enteropathy-associated T cell lymphoma,
which in itself is well documented in CD [5].
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Two years after resolution of HLH, a diagnosis of sero-
negative JIA was made and treatment instigated in this pa-
tient. It could therefore also be argued that her HLH was
secondary to JIA. However, she had no diagnostic features
of JIA at first presentation, and demonstrated a good clin-
ical response to standard HLH treatment. Following re-
lapse of her hyperferritinemia she demonstrated complete
resolution of symptoms and laboratory findings with the
introduction of a gluten-free diet. After further exposure
to gluten her symptoms returned. JIA is known to have
an association with CD, the latter increasingly being
understood as a multisystem disorder with many pos-
sible immunological manifestations [4]; however, an as-
sociation of HLH with response to gluten withdrawal
has not previously been described.
Conclusions
The association of HLH and CD, with clinical response
to gluten withdrawal, has not been reported in the litera-
ture. This case is noteworthy due to the absence of labora-
tory features of primary HLH, temporary resolution of
symptoms following anti-HLH therapy, rapid relapse upon
cessation of HLH therapy, and full clinical and biochem-
ical resolution following a gluten-free diet.
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Fig. 1 Timeline demonstrating clinical course with concurrent age. HLH hemophagocytic lymphohistiocytosis, JIA juvenile idiopathic arthritis
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